A Phase 4 interventional study of Acetylsalicylic acid (ASA)/aspirin 100 mg daily and Clopidogrel 75 mg daily in Ischemic Stroke, sponsored by Azienda Usl di Bologna. Not yet recruiting at 3 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Azienda Usl di Bologna · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.
Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 10th largest by planned enrollment of the 50 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 4, reaches primary completion later than 26 of the 28 other live ones, and was the 81st registered.
2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.
Browse Ischemic Stroke studies →23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:
Hospital Universitari Vall d'Hebron Research Institute · Sites in Italy, Belgium, Germany and 3 more countries
Ages 18+
Niguarda Hospital · Sites in Italy
Ages 18+
Azienda Usl di Bologna · Sites in Italy
Ages 18+
Italian Society of Vascular and Endovascular Surgery · Sites in Italy
Ages 45–90
Corxel Pharmaceuticals · Sites in Italy, United States, Belgium and 18 more countries
Ages 18–90
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 10 · Phase 4 5
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,506 is above the median of 120 across 1,781 interventional studies indexed under Ischemic Stroke.
Median enrollment 227 across the 50 interventional studies, 550 across the 30 observational. Of the 40 that completed or were terminated, 12 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 81 have an industry lead sponsor. The 10 most frequent:
Azienda Usl di Bologna is the lead sponsor of 44 studies on the registry; 14 are open to participants now.
Azienda Usl di Bologna has 4 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
7 of the studies in Ischemic Stroke with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06710028Fondazione Policlinico Universitario Agostino Gemelli IRCCSTrustworthy Artificial Intelligence for Improvement of Stroke Outcomes | 2026-11-30 |
| NCT07199322Fondazione Don Carlo Gnocchi ETSClinical validatiOn of an AI-based DEcision Support System for Robotic Upper Limb Rehabilitation in Patients With Stroke. A CO-AIDER Study. | 2026-12 |
| NCT04562194VesalioNeVa ONE Registry Study | 2026-12-31 |
| NCT04339699Nobles Medical Technologies II IncNobleStitch EL STITCH Trial is a PFO Comparative Trial | 2026-12-31 |
| NCT06823466University of L'AquilaAdvancing Knowledge in Ischemic Stroke Patients on Oral Anticoagulants | 2027-02-12 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Ischemic Stroke with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TAILOR study aims to determine whether personalized antiplatelet therapy can reduce the risk of recurrent major cardiovascular events in patients who have experienced (a non-cardioembolic ischemic stroke).
Antiplatelet medications, such as aspirin and clopidogrel, are commonly prescribed to prevent stroke recurrence. However, some patients do not respond adequately to these medications and may remain at increased risk of further cardiovascular events.
The study will compare two approaches to antiplatelet therapy: standard care, in which medications are prescribed according to current clinical practice, and personalized care (tailored care), in which treatment is adjusted based on a blood test measuring how effectively the medication inhibits platelet activity.
Participants will be randomly assigned to one of these two treatment strategies and followed for 12 months.
The main hypothesis is that tailoring antiplatelet therapy according to individual platelet response will be more effective than standard care in preventing recurrent ischemic stroke, myocardial infarction, or cardiovascular death. The study will also explore potential differences in treatment response between women and men.
Antiplatelet therapy is a cornerstone of secondary prevention following non-cardioembolic ischemic stroke. However, a substantial proportion of patients experience recurrent cardiovascular events despite receiving guideline-recommended antiplatelet treatment. One potential explanation is inadequate biological response to antiplatelet agents, commonly referred to as antiplatelet resistance. Previous observational studies have suggested that reduced responsiveness to aspirin or clopidogrel is associated with an increased risk of recurrent vascular events.
In current clinical practice, antiplatelet medications are generally prescribed without routinely assessing individual platelet response. Platelet function testing may provide an opportunity to personalize antiplatelet therapy by identifying patients with inadequate pharmacological response and guiding treatment adjustments. Furthermore, biological sex may influence antiplatelet responsiveness and treatment effectiveness, supporting the need to investigate potential sex-related differences in personalized secondary prevention strategies.
The TAILOR trial is a multicenter, phase IV, randomized, controlled, pragmatic, open-label trial with blinded endpoint assessment, designed to investigate whether antiplatelet therapy guided by platelet function testing provides greater protection against recurrent cardiovascular events than conventional antiplatelet management.
A total of 1,506 participants will be recruited across three Italian stroke centers and randomly assigned in a 1:1 ratio to a personalized antiplatelet treatment strategy (tailored care) or conventional antiplatelet management (usual care). Randomization will be performed centrally using a computer-generated allocation procedure, with balancing factors including study center, sex, baseline stroke severity, and initial antiplatelet treatment.
Participants will be enrolled within 7 days of the index ischemic stroke and will undergo a run-in period of at least 7 days of antiplatelet therapy according to usual care (10 days for patients receiving dual antiplatelet therapy). Randomization will take place within 14 days of the index event, after re-assessment of eligibility criteria at the end of the run-in period. Immediately after randomization, platelet function will be evaluated using multiple electrode aggregometry. The Multiplate Analyzer measures platelet aggregation in response to specific agonists, including arachidonic acid (ASPI test) and adenosine diphosphate (ADP test). These measurements provide information on the biological response to aspirin and clopidogrel, respectively.
In the tailored care group, antiplatelet therapy will be maintained or modified according to platelet function test results. Participants demonstrating an adequate biological response will continue their current treatment, whereas those showing insufficient platelet inhibition will be switched to an alternative approved antiplatelet agent, according to the predefined treatment algorithm.
In the usual care group, participants will continue conventional antiplatelet treatment independently of platelet function test results. Treating physicians in this group will remain unaware of the aggregometry findings.
The antiplatelet agents used in the trial include aspirin, clopidogrel, and ticlopidine, administered according to their approved indications and dosing regimens. All participants will continue to receive other appropriate secondary stroke prevention measures in accordance with current clinical guidelines.
Participants will be followed for 12 months after randomization. Clinical assessments will be conducted during follow-up, including evaluations of treatment adherence, functional status, cardiovascular events, and treatment-related safety. Endpoint assessments will be performed by personnel blinded to treatment allocation.
In addition, CYP2C19 genetic variants associated with clopidogrel metabolism will be investigated to explore their relationship with platelet responsiveness. Prespecified analyses will also examine potential differences in treatment response and clinical outcomes between female and male participants.
By integrating platelet function testing into antiplatelet treatment decisions, the TAILOR trial aims to generate evidence on the clinical value of a personalized approach to secondary stroke prevention using medications already approved and routinely available in clinical practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will continue the antiplatelet therapy (aspirin or clopidogrel) started after the index stroke, according to usual care, independently of platelet aggregation test results. Platelet function testing is performed in all participants, but results are not disclosed to treating physicians in this arm. Patients receiving short-term DAPT will continue, at the end of the 10-day run-in period, with the single antiplatelet agent indicated by usual care (aspirin or clopidogrel), regardless of platelet aggregation test results.
Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily · Drug: Clopidogrel 75 mg daily · Drug: Ticlopidine 250 mg twice daily
Based on platelet aggregation test results (Multiplate ASPI and ADP tests), antiplatelet therapy will be tailored as follows: 1. If taking aspirin and the test confirms responsiveness, aspirin is continued. 2. If taking clopidogrel and the test confirms responsiveness, clopidogrel is continued. 3. If taking aspirin and the test shows non-responsiveness, therapy is switched to clopidogrel or ticlopidine. 4. If taking clopidogrel and the test shows non-responsiveness, therapy is switched to aspirin or ticlopidine. Patients with an indication to short-term dual antiplatelet therapy (DAPT; minor stroke with NIHSS ≤3) will undergo a 10-day run-in period and then continue with single antiplatelet therapy: patients due to continue aspirin will switch to clopidogrel if non-responders to aspirin; patients due to continue clopidogrel will switch to ticlopidine if non-responders to clopidogrel.
Drug: Acetylsalicylic acid (ASA)/aspirin 100 mg daily · Drug: Clopidogrel 75 mg daily · Drug: Ticlopidine 250 mg twice daily
Aspirin acts as an irreversible inhibitor of COX-1/-2 enzymes, decreasing prostaglandin precursors formation and inhibiting platelet aggregation. It is the most prescribed medication for cardio-cerebrovascular diseases prevention, as this has been the first antiplatelet with demonstrated effectiveness and safety (Rothlisberger and Ovbiagele, 2015).
Clopidogrel works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes (Rothlisberger and Ovbiagele, 2015).
Ticlopidine has a mechanism of action similar to Clopidogrel, as it works by irreversibly blocking the P2Y12 component of ADP receptors on platelets preventing the activation of GPIIb/IIIa receptor complexes. However it takes longer time to reach the maximal effect (Rothlisberger and Ovbiagele, 2015).
Major Cardiovascular Event at 12 months
Time to the first occurrence of a composite event comprising ischemic stroke, myocardial infarction, or cardiovascular death within 3 months after randomization. The outcome will be assessed as time to first event (days) and cumulative incidence (percentage of participants experiencing at least one event).
Time frame: From randomization to 12 months
Major Cardiovascular Events at 3 Months
Time to the first occurrence of a composite event comprising ischemic stroke, myocardial infarction, or cardiovascular death within 3 months after randomization. The outcome will be assessed as time to first event (days) and cumulative incidence (percentage of participants experiencing at least one event).
Time frame: From randomization to 3 months
Medication Adherence
Percentage of participants (%) with good medication adherence, defined as a score ≥20 on the 5-item Medication Adherence Report Scale (MARS-5). Total scores range from 5 to 25, with higher scores indicating better adherence.
Time frame: At 3 and 12 months after randomization
Platelet responsiveness
Percentage of participants (%) demonstrating adequate biological response to the ongoing antiplatelet therapy, assessed by multiple electrode aggregometry (Multiplate Analyzer) using the arachidonic acid-induced (ASPI) test for aspirin and the adenosine diphosphate-induced (ADP) test for clopidogrel/ticlopidine. Platelet aggregation is measured in aggregation units (U); adequate response is defined as ASPI \<40 U for aspirin and ADP \<46 U for P2Y12 inhibitors.ocol thresholds.
Time frame: At 12 months after randomization
Good functional status
Good functional status is measured at 12 months, being defined and adjudicated according to modified Rankin Scale 0-2. The mRS ranges from 0 (no symptoms) to 6 (death), with lower scores indicating better functional status.
Time frame: At 12 months after randomization
Incidence of Major Bleeding
Percentage of participants experiencing at least one major bleeding event, defined according to the International Society on Thrombosis and Haemostasis (ISTH) criteria as fatal bleeding, and/or symptomatic bleeding in a critical area or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome), and/or bleeding causing a fall in hemoglobin of 20 g/L or more, or leading to transfusion of 2 or more units of whole blood or red cells. Major bleeding events are a component of the composite safety outcome.
Time frame: From randomization to 12 months
Incidence of Minor Bleeding
Percentage of participants experiencing at least one minor bleeding event, defined as any reported bleeding not classified as major according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Minor bleeding events are a component of the composite safety outcome.
Time frame: From randomization to 12 months
Incidence of Ischemic Stroke
Percentage of participants experiencing at least one recurrent ischemic stroke within 12 months after randomization.
Time frame: From randomization to 12 months
Incidence of Myocardial Infarction
Percentage of participants experiencing at least one myocardial infarction within 12 months after randomization.
Time frame: From randomization to 12 months
Incidence of Cardiovascular Death
Percentage of participants who die from cardiovascular causes within 12 months after randomization.
Time frame: From randomization to 12 months
Gender differences in the primary and secondary outcomes
Assessment of differences in the incidence of primary and secondary clinical outcomes between female and male participants, expressed as the percentage of participants experiencing each event in each sex subgroup.
Time frame: From randomization to 12 months
Prevalence of CYP2C192 and CYP2C1917 Genetic Variants
Percentage of participants carrying the CYP2C19\*2 (rs4244285) or CYP2C19\*17 (rs12248560) genetic variant, assessed separately among responders and non-responders to antiplatelet therapy. Genotypes will be determined from blood samples using TaqMan SNP genotyping assays.
Time frame: At Baseline
Start is estimated for Dec 2026; primary completion for Dec 2029, 36 months later.
Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 36 months is above that.
Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Usl di Bologna